Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Vaxcyte Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Vaxcyte şirketinin kazançları yıllık ortalama -48.2% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında arttı.

Anahtar bilgiler

-48.2%

Kazanç büyüme oranı

33.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-25.0%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Dec 22

Vaxcyte appoints new CBO, CMO

Oct 11

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Aug 05

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Feb 25

Gelir ve Gider Dağılımı

Vaxcyte nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:PCVX Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	-497	74	428
31 Mar 24	-437	67	369
31 Dec 23	-402	61	332
30 Sep 23	-300	55	280
30 Jun 23	-265	50	230
31 Mar 23	-245	45	196
31 Dec 22	-223	40	169
30 Sep 22	-174	35	141
30 Jun 22	-143	30	114
31 Mar 22	-118	27	93
31 Dec 21	-100	25	78
30 Sep 21	-92	23	70
30 Jun 21	-87	22	66
31 Mar 21	-83	19	67
31 Dec 20	-89	16	74
30 Sep 20	-83	14	72
30 Jun 20	-73	11	66
31 Mar 20	-64	11	57
31 Dec 19	-50	9	46
31 Dec 18	-29	5	30

Kaliteli Kazançlar: PCVX şu anda kârlı değil.

Büyüyen Kar Marjı: PCVX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PCVX kârlı değildir ve zararlar son 5 yılda yılda 48.2% oranında artmıştır.

Büyüme Hızlandırma: PCVX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: PCVX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: PCVX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -25.03% ) sahiptir.

Vaxcyte Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Recent updates

Co-Founder notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

Executive VP & COO notifies of intention to sell stock

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Price target increased by 27% to US$131

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

President & CFO notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte Appoints John Furey to Board of Directors

President & CFO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

President & CFO notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Price target increased by 7.8% to US$71.14

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Co-Founder notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Senior VP notifies of intention to sell stock

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

President & CFO notifies of intention to sell stock

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Co-Founder notifies of intention to sell stock

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

President exercised options to buy US$1.1m worth of stock.

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Executive VP & COO exercised options to buy US$5.1m worth of stock.

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

Independent Director exercised options and sold US$131k worth of stock

High number of new directors

Price target increased to US$60.50

Independent Director exercised options and sold US$147k worth of stock

Price target increased to US$56.00

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte appoints new CBO, CMO

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate